Evidence map›Paper›PMID 36306678›Full record

ArticleThrombosis research2022

Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE).

Parker Knueppel, Seo Hyoun Bang, Camille Troyer, Alyssa Barriga, Jaekyu Shin, Christine L Cadiz, Connie Abdo, Taylor McCart, Brittany Huynh, Craig Stevens and 4 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Parker KnueppelUniversity of California, Davis Health, 2420 Stockton Blvd, Ste 2000, Sacramento, CA 95817, USA. Electronic address: pjknueppel@ucdavis.edu.
Seo Hyoun BangUniversity of California, San Diego Health, 200 W Arbor Dr, San Diego, CA 92103, USA. Electronic address: sbang@health.ucsd.edu.
Camille TroyerUniversity of California, San Francisco Health, 521 Parnassus Ave, Rm 3304, San Francisco, CA 94143, USA. Electronic address: cjtroyer@health.ucsd.edu.
Alyssa BarrigaUniversity of California, Irvine School of Pharmacy & Pharmaceutical Sciences, 515 Bison Modular 147C, Irvine, CA 92697, USA. Electronic address: ajbarrig@hs.uci.edu.
Jaekyu ShinUniversity of California, San Francisco Health, 521 Parnassus Ave, Rm 3304, San Francisco, CA 94143, USA. Electronic address: jaekyu.shin@ucsf.edu.
Christine L CadizUniversity of California, Irvine School of Pharmacy & Pharmaceutical Sciences, 515 Bison Modular 147C, Irvine, CA 92697, USA. Electronic address: christine.cadiz@uci.edu.
Connie AbdoUniversity of California, Irvine School of Pharmacy & Pharmaceutical Sciences, 515 Bison Modular 147C, Irvine, CA 92697, USA. Electronic address: cabdo1@hs.uci.edu.
Taylor McCartUniversity of California, San Francisco Health, 521 Parnassus Ave, Rm 3304, San Francisco, CA 94143, USA. Electronic address: taylor.mccart@ucsf.edu.
Brittany HuynhUniversity of California, San Francisco Health, 521 Parnassus Ave, Rm 3304, San Francisco, CA 94143, USA. Electronic address: brittany.huynh@ucsf.edu.
Craig StevensUniversity of California, San Diego Health, 200 W Arbor Dr, San Diego, CA 92103, USA. Electronic address: c2stevens@health.ucsd.edu.
Crystal ZhouUniversity of California, San Francisco Health, 521 Parnassus Ave, Rm 3304, San Francisco, CA 94143, USA. Electronic address: crystal.zhou@ucsf.edu.
Nuen Tsang YangUniversity of California, Davis Health, 2420 Stockton Blvd, Ste 2000, Sacramento, CA 95817, USA. Electronic address: matyang@ucdavis.edu.
Machelle WilsonUniversity of California, Davis Health, 2420 Stockton Blvd, Ste 2000, Sacramento, CA 95817, USA. Electronic address: mdwilson@ucdavis.edu.
Tiffany PonUniversity of California, Davis Health, 2420 Stockton Blvd, Ste 2000, Sacramento, CA 95817, USA; University of California, San Francisco Health, 521 Parnassus Ave, Rm 3304, San Francisco, CA 94143, USA. Electronic address: tkpon@ucdavis.edu.
University of California, San Francisco · USUniversity of California, Irvine · USUC San Diego Health System · USUniversity of California, Davis · USUniversity of California, San Diego · US

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
NCATS NIH HHS UL1 TR001860
6 · The paper itself

Abstract

backgroundThere are no clear dosing recommendations when using apixaban for venous thromboembolism (VTE) treatment in patients with severe or end-stage renal disease; clinical trials excluded patients with a creatinine clearance (CrCl) <25 mL/min or on dialysis. This study compares bleeding rates in patients with severe or end-stage renal disease taking standard versus reduced dose apixaban for VTE treatment. MATERIALS AND

methodsThis was a multicenter, retrospective cohort study using electronic medical records between January 1, 2013, and August 31, 2021. This study included patients 18 years or older who had severe or end-stage renal disease when prescribed apixaban for VTE treatment. Severe or end-stage renal disease was defined as at least one of the following: CrCl <25 mL/min, SCr >2.5 mg/dL, CKD stage 4 or 5, or on dialysis. The primary endpoint was rate of clinically relevant bleeding within six months of starting apixaban. Secondary endpoints were VTE recurrence within six months of starting apixaban, time to clinically relevant bleed, and time to VTE recurrence.

resultsA total of 203 patients were included in the final analysis (n = 125 on 5 mg; n = 78 on 2.5 mg). Clinically relevant bleeding rate was significantly higher in the standard dose group (14.4 % vs 3.8 %, p = 0.02). Rates of VTE recurrence appear similar (6.4 % vs 7.7 %, p = 0.21).

conclusionsA reduced dose of apixaban may be considered when treating VTE in patients with severe or end-stage renal disease.

Indexed as

Kidney Failure, ChronicVenous ThromboembolismAnticoagulantsHemorrhageHumansPyrazolesPyridonesRetrospective StudiesAnticoagulantsapixabanPyrazolesPyridonesAnticoagulationApixabandialysisRenal diseaseVenous thromboembolism

Identifiers

PMID36306678
PMCPMC9850596
OpenAlexW4307848216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.